Evidence map›Paper›PMID 29661231›Full record

ArticleParasites & vectors2018

Surveillance for lymphatic filariasis after stopping mass drug administration in endemic districts of Togo, 2010-2015.

Monique Ameyo Dorkenoo, Rachel Bronzan, Degninou Yehadji, Mawèke Tchalim, Kossi Yakpa, Santrao Etassoli, Poukpessi Adjeloh, Issaka Maman, Yao Sodahlon

Open access · goldAbstract read
In one paragraph

Article in Parasites & vectors, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 3 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 3 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Monique Ameyo DorkenooFaculté des Sciences de la santé, Université de Lomé, BP 1515, Lomé, Togo. monicadork@yahoo.fr.
Rachel BronzanHealth and Development International (HDI), Newburyport, MA, USA.
Degninou YehadjiProgramme National d'Elimination de la Filariose Lymphatique, Ministère de la Santé et de la Protection Sociale, Angle avenue Sarakawa et Avenue du 24 Janvier, BP 336, Lomé, Togo.
Mawèke TchalimProgramme National d'Elimination de la Filariose Lymphatique, Ministère de la Santé et de la Protection Sociale, Angle avenue Sarakawa et Avenue du 24 Janvier, BP 336, Lomé, Togo.
Kossi YakpaProgramme National de Lutte contre le Paludisme, BP 518, Lomé, Togo.
Santrao EtassoliProgramme National d'Elimination de la Filariose Lymphatique, Ministère de la Santé et de la Protection Sociale, Angle avenue Sarakawa et Avenue du 24 Janvier, BP 336, Lomé, Togo.
Poukpessi AdjelohProgramme National de Lutte contre le Paludisme, BP 518, Lomé, Togo.
Issaka MamanLaboratoire de référence, Institut National d'Hygiène, BP 1396, Lomé, Togo.
Yao SodahlonMectizan Donation Program, 325 Swanton Way, Decatur, GA, 30030, USA.
Togolese Ministry of Health · TGHealth & Development International · USUniversity of Lomé · TG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTogo is a country previously endemic for lymphatic filariasis (LF). In 2010, following nine years of mass drug administration (MDA) for LF, the country established a post-treatment surveillance (PTS) system. We present here the results of these PTS activities, carried out from 2010 to 2015, as well as the findings of follow-up investigations in 2016 to confirm the absence of infection in previously infected individuals.

methodsThe routine surveillance established in 2010 consisted of a network of 47 laboratories, which searched for Wuchereria bancrofti microfilaria on nocturnal blood smears collected for malaria diagnosis and an additional network of 20 peripheral health facilities, which collected dried blood spots and tested them for Og4C3 antigen. Two transmission assessment surveys (TAS) were also undertaken, as recommended by WHO, in 2012 and 2015. Any positive case identified through any surveillance activity was immediately retested by nocturnal smear and confirmed cases were immediately investigated by screening family members and neighboring household members. In 2016, 32 of the 40 positive cases detected during TAS or laboratory and health facility network activities were traced and whether confirmed positive by nocturnal smear or not were tested again simultaneously by filariasis test strip (FTS), Og4C3 and a nocturnal blood smear to rule out any active infection.

resultsFrom 2010 to 2015, the laboratory network identified one microfilaria-positive individual (0.0% of 26,584 persons tested) and the peripheral health facility network detected 19 Og4C3-positive individuals (0.28% of 6788 persons tested). All 19 Og4C3 cases were negative for microfilaremia by nocturnal blood smear. In the 2012 and 2015 TAS, thirteen and six ICT/FTS positive cases, respectively, were identified, which were significantly below the critical cut-off (18-20 cases) across all evaluation units. Three of the six ICT/FTS-positive cases from the 2015 TAS were positive by nocturnal smear; immediate investigation identified one additional microfilaria-positive individual. Epidemiological investigation revealed that four of the five cases of microfilaremia were imported from another country in the region. In 2016, 32 of the 40 positive cases detected by at least one test during all surveillance activities were traced: four (12.5%) individuals were still positive by FTS but all 32 individuals were negative for microfilaremia and Og4C3 antigen.

conclusionThe results of post-treatment surveillance in Togo have demonstrated that W. bancrofti filariasis is no longer of public health concern in Togo, more than six years after stopping MDA. Every possible effort should be made to maintain surveillance in order to promptly detect any resurgence and preserve this achievement.

Indexed as

Epidemiological MonitoringHealth Services ResearchMass Drug AdministrationAnimalsBloodElephantiasis, FilarialFilaricidesMicroscopyParasitologyTogoWuchereria bancroftiFilaricidesLymphatic filariasisMass drug administrationPost-treatment surveillanceTogoTransmission assessment survey

Identifiers

PMID29661231
PMCPMC5902853
OpenAlexW2801602499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.